Search Results

TerSera Therapeutics announced a new sponsorship with the Carcinoid Cancer Foundation and Alira Health to expand and optimize a holistic patient journey digital platform for patients with Neuroendocrine Tumors and Carcinoid Syndrome.

December 7, 2022

·

7 min read

BioMidwest

TerSera® Announces Publication Of Real-World Study On Xermelo® (Telotristat Ethyl) In Patients With Carcinoid Syndrome Diarrhea

TerSera Therapeutics LLC announced today the online publication of the TELEPRO-II study in the Journal of Cancer Management and Research.

October 27, 2021

·

7 min read

Health Canada Approves ZOLADEX® LA for the Management of Estrogen Receptor-Positive (ER+) Early Breast Cancer with a High Risk of Recurrence or Advanced Breast Cancer in Pre- and Perimenopausal Women

TerSera Canada Inc. today announced that Health Canada has approved a supplemental New Drug Submission for ZOLADEX LA (goserelin acetate) 10.8mg every 12 weeks for the management of estrogen receptor-positive (ER+) early breast cancer with a high risk of recurrence or advanced breast cancer in pre- and perimenopausal women.

May 7, 2024

·

4 min read

BioMidwest

TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (telotristat ethyl): Long-Term Registry Trial of Patients with Carcinoid Syndrome Diarrhea

TerSera Therapeutics LLC announced today the presentation of patient-reported clinical and productivity outcomes data from their registry trial (RELAX) in patients with carcinoid syndrome diarrhea (CSD) receiving treatment with Xermelo (telotristat ethyl).

November 9, 2021

·

7 min read

Deals

Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics

Lexicon Pharmaceuticals, Inc. announced the completion of the sale of Lexicon’s rights, title and interest in XERMELO® to TerSera Therapeutics LLC.

September 8, 2020

·

3 min read